167 related articles for article (PubMed ID: 37270458)
1. In vitro chemo-preventive efficacy of synthetic progestin Norethindrone in human epithelial ovarian cancer.
Sharma A; Sharma I
Med Oncol; 2023 Jun; 40(7):195. PubMed ID: 37270458
[TBL] [Abstract][Full Text] [Related]
2. Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth.
Gu M; Wang L; Yang C; Li X; Jia C; Croteau S; Ruan X; Hardy P
Maturitas; 2018 Aug; 114():60-66. PubMed ID: 29907248
[TBL] [Abstract][Full Text] [Related]
3. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
4. Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Hyder SM; Murthy L; Stancel GM
Cancer Res; 1998 Feb; 58(3):392-5. PubMed ID: 9458078
[TBL] [Abstract][Full Text] [Related]
5. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
6. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
7. The effects of progesterone and progestins on endometrial proliferation.
Moyer DL; Felix JC
Contraception; 1998 Jun; 57(6):399-403. PubMed ID: 9693400
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
9. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high density lipoprotein-cholesterol.
Song S; Chen JK; Lu CH; Yang PJ; Yang QY; Fan BC; He ML; Gui YL; Li LM; Fotherby K
Contraception; 1993 Jun; 47(6):527-37. PubMed ID: 8334889
[TBL] [Abstract][Full Text] [Related]
10. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
12. The progestogen-only mini-pill.
Graham S; Fraser IS
Contraception; 1982 Oct; 26(4):373-88. PubMed ID: 6759029
[TBL] [Abstract][Full Text] [Related]
13. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
14. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells.
Ruan X; Neubauer H; Yang Y; Schneck H; Schultz S; Fehm T; Cahill MA; Seeger H; Mueck AO
Climacteric; 2012 Oct; 15(5):467-72. PubMed ID: 22335423
[TBL] [Abstract][Full Text] [Related]
15. A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids.
Stanczyk FZ; Brenner PF; Mishell DR; Ortiz A; Gentzschein EK; Goebelsmann U
Contraception; 1978 Dec; 18(6):615-33. PubMed ID: 750188
[TBL] [Abstract][Full Text] [Related]
16. Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins.
Tatsumi H; Kitawaki J; Tanaka K; Hosoda T; Honjo H
Maturitas; 2002 Aug; 42(4):287-94. PubMed ID: 12191851
[TBL] [Abstract][Full Text] [Related]
17. Is there a protective role of progestogens on the proliferation of human ovarian cancer cells in the presence of growth factors?
Seeger H; Wallwiener D; Mueck AO
Eur J Gynaecol Oncol; 2006; 27(2):139-41. PubMed ID: 16620055
[TBL] [Abstract][Full Text] [Related]
18. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.
Liang Y; Besch-Williford C; Brekken RA; Hyder SM
Cancer Res; 2007 Oct; 67(20):9929-36. PubMed ID: 17942925
[TBL] [Abstract][Full Text] [Related]
19. Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.
Hovanessian-Larsen L; Taylor D; Hawes D; Spicer DV; Press MF; Wu AH; Pike MC; Pearce CL
Contraception; 2012 Sep; 86(3):238-43. PubMed ID: 22325110
[TBL] [Abstract][Full Text] [Related]
20. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
